<DOC>
	<DOCNO>NCT01981811</DOCNO>
	<brief_summary>The purpose study evaluate adherence treatment , safety tolerability , medical information device # 1 ( MIND1 ) system subject Schizophrenia Bipolar I Disorder currently treat oral aripiprazole .</brief_summary>
	<brief_title>Adherence Treatment , Safety Tolerability Study Medical Information Device # 1 ( MIND1 ) Subjects With Schizophrenia Bipolar I Disorder</brief_title>
	<detailed_description>Poor adherence medication well-recognized problem psychiatric patient barrier achieve optimal health . The MIND1 System develop objectively precisely monitor measure real-time medication adherence ; potentially enhance adherence . The MIND1 System include oral aripiprazole embed ingestible event marker ( IEM ) , Wearable Sensor , computerized device accessory . This trial design evaluate adherence treatment , safety tolerability , medical information device # 1 ( MIND1 ) system subject schizophrenia bipolar I disorder . This 12-week , single-arm trial include male female subject 18 65years ( inclusive ) current diagnosis schizophrenia bipolar I disorder currently treat oral aripiprazole .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Males females 18 65 year age , inclusive , time informed consent Schizophrenia : Patients two exacerbation symptom past year lead intervention , per investigator 's judgment ( ie , inpatient psychiatric hospitalization , psychiatric ER visit , admission partial hospitalization program , crisis residential treatment , etc. ) . This include outpatient adjustment medication . Bipolar I Disorder : Patients least one manic episode exacerbation bipolar symptom past year result intervention , per Investigator 's judgment ( i.e. , inpatient psychiatric hospitalization , psychiatric ER visit , admission partial hospitalization program , crisis residential treatment , etc . ) This include outpatient adjustment medication . Current primary Axis1 diagnosis bipolar 1 disorder schizophrenia define DSMIVTR criterion Bipolar 1 disorder patient total YMRS score 10 25 ( inclusive ) Schizophrenia patient total PANSS score 60 90 ( inclusive ) Currently prescribe oral Aripiprazole either bipolar 1 disorder schizophrenia . No change Aripiprazole dose regimen 2 week screen . Subjects must able tolerate blood draw . If subject psychotropic medication , he/she must stable dose regimen last 2 week . Subjects current Axis I ( DSMIVTR ) diagnosis bipolar 1 disorder schizophrenia Subjects current Axis II ( DSMIVTR ) diagnosis History inpatient hospitalization psychiatric reason within 2 month screen Subjects reside attend facility medication administer Subject receive investigational product within last 30 day Allergic , intolerant , unresponsive prior treatment Aripiprazole quinolinones History hypersensitivity antipsychotic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>OPC-14597 Digital</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Medical Information Device # 1 System ( MIND1 )</keyword>
	<keyword>Treatment Adherence</keyword>
	<keyword>Ingestible Event Marker</keyword>
</DOC>